Preterm Birth Control Market Size, Share, Industry Growth 2025

report image

Preterm Birth Control Market to 2025 - Global Analysis and Forecasts By Treatment Method (Devices and Pharmaceutical Treatment), and Geography

Publication Month: Sep 2018 | Report Code: TIPMD00002026 | No. of Pages: 115 | Category: Medical Device | Status: Published

The global preterm birth control market is expected to reach US$ 1,809.0 Mn in 2025 from US$ 1,190.5 Mn in 2017. The market is estimated to grow with a CAGR of 4.9% from 2018-2025.

North America is the largest geographic market and it is expected to be the largest revenue generator during the forecast period, whereas the market is expected to witness growth at a significant rate in Asia Pacific (APAC) region during the forecast period. The Asia Pacific per-term birth control market is expected to grow with CAGR of 5.1% to US$ 325.6 Mn in 2025 from US$ 222.4 Mn in 2017.

 Lucrative Regional Markets

Get more information on this report :


Market Insights

Increasing Number of Preterm Births

There has been a gradual increase in the number of preterm births from last few years. As per the World Health Organization (WHO), premature birth is a leading cause of death among the child below 5 years of age. It may be due to early induction of labor or caesarean birth. Multiple pregnancies, infections and chronic conditions such as diabetes and high blood pressure are others common causes of preterm births. As per the Centers for Disease Control and Prevention (CDC), reduction in preterm birth was observed from 2007-2014. In 2015, low birth weight and preterm birth accounted for about 17% of infant deaths. However, the number increased during 2016, with racial and ethnic differences. In the US, 1 of every 10 infants born was a preterm birth.

Initiatives towards Prevention of Preterm Birth


A number of government and non-government organizations are engaged increasing awareness about preterm birth in various countries across the globe. Organizations such as CDC has implemented strategies to reduce preterm births. These strategies includes provision of healthcare services before and between pregnancies; determining population at the risk of preterm delivery and provide immediate treatment, discouraging deliveries before 39 weeks without a medical need; and preventing unintended pregnancies by waiting for at least 18 months between pregnancies.

Stringent Regulatory Framework


Regulatory authorities such as Food & Drug Administration (FDA), European Medicine Agency (EMA) and others has consistently shown a tough stance towards pharmaceutical can biotechnology manufacturers. The market players must comply with the requirement and guidelines of FDA and other regulatory authorities and should constantly keep a check over time to time changes made in these guidelines. The manufacturers of pharmaceutical drugs and medical devices must abide by these regulations pertaining to current good manufacturing practices (cGMP) as well as good laboratory practices (GLP) in order to assure proper design, monitoring, and control of manufacturing processes and facilities. Furthermore, any deviations from the registered protocols, demands and requirements of these guidance leads to termination of the clinical trials undertaken by the pharmaceutical companies.

Additionally, FDA also requires strong safety monitoring and a strict dispensing plan to be followed by the manufacturer. Non-compliance by the manufacturers affects the sales of the products in the market and may lead to the recalls for marketed products due to instances recorded for deficit of the promises in the function and performance of the product or therapeutic may tarnish the company’s reputation risking its future growth. In case of clinical trials for development of therapeutics for preterm birth control, the FDA and other regulatory bodies have strict regulations due to which it is difficult for the manufacturers to pool in pregnant patients generating lack of working models. This in turn results into rejection of trials and can thus act as hindrance to the market growth.

Product Insights


The pre-term birth control market by treatment method is segmented into pharmaceutical treatment and devices. The pharmaceutical treatment segment is poised to grow with a largest market share of 55.6% in 2017. The market for pharmaceutical treatment is anticipated to surge during the forecast period from 2017 to 2025, at a significant rate.

 Pre-term birth control Market, by Treatment method

Get more information on this report :



Strategic Insights

Report Coverage - Preterm Birth Control Market
Report CoverageDetails
Market Size Value inUS$ 1,190.5 Million in 2017
Market Size Value byUS$ 1,809.0 Million by 2025
Growth rateCAGR of 4.9% from 2018-2025
Forecast Period2018-2025
Base Year2018
No. of Pages115
No. of Tables40
No. of Charts & Figures43
Historical data availableYes
Segments coveredTreatment Method , and Geography
Regional scopeNorth America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country scopeUS, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina
Report coverageRevenue forecast, company ranking, competitive landscape, growth factors, and trends
Free Sample Copy Available

Collaborations/ acquisitions were observed as the most adopted strategy in global pre-term birth control industry. Few of the product launches and agreements made by the players in the market are listed below;

2018: CooperSurgical had acquired the assets of The LifeGlobal Group and its affiliates. The LifeGlobal Group is a leading global provider of in-vitro fertilization devices.

PRE-TERM BIRTH CONTROL – MARKET SEGMENTATION

By Treatment method

  • Devices
  • Cervical Cerclage
  • Vaginal Pessaries
  • Pharmaceutical treatment

By Geography

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • U.K
  • Asia Pacific
    • Japan
    • China
    • India
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
  • South & Central America
    • Argentina
    • Brazil

Company Profiles

  • Cooper Surgical
  • Medgyn Products
  • Integra Life sciences Corporation
  • Panpac Medical Corp.
  • Dr. Arabin GMBH & Co. KG
  • Amag Pharmaceuticals
  • Ben Way Enterprises Sdn Bhd
  • Personal Medical Corp.
  • Bioteque America Inc.
  • Bliss Gvs Pharma Ltd.

The List of Companies

  1. CooperSurgical, Inc.
  2. MEDGYN PRODUCTS, INC.
  3. Integra LifeSciences Corporation
  4. Panpac Medical Corp.
  5. Personal Medical Corp
  6. Bioteque America, Inc.
  7. Bliss GVS Pharma Ltd.
  8. Dr. Arabin GmbH & Co. KG
  9. AMAG Pharmaceuticals
  10. BEN WAY ENTERPRISES SDN BHD
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the preterm birth control market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global preterm birth control market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
TIPMD00002026
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market




christmas_festive_offer

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
Pricing
  • $3000 $2700
  • $4550 $3000
  • $6550 $4000
  • $8550 $5000

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount